Compare Mondaycom Ltd (MNDY) vs Moderna, Inc. (MRNA) Price & Performance

Monday.com (MNDY) trades at $88.96, up 6.53% in the last session, showing strong momentum after recent earnings beats. The stock maintains bullish technical signals with support at $86 and resistance at $90. Fundamentally, the company demonstrates robust revenue growth reaching $1.23 billion in 2025 with impressive 88.74% gross margins, though valuation multiples remain elevated with a P/E of 37.69. Recent news highlights the company's AI initiatives at its Elevate '26 conference and inclusion in multiple growth stock lists.

The outlook remains positive with Wall Street consensus at $108.64 target price and 65% buy ratings, though risks include competitive pressure from Meta's enterprise push and elevated valuation multiples. Earnings momentum continues with three consecutive quarterly beats, but investors should monitor the upcoming Q3 2026 results against $1.37 EPS expectations for continued validation of growth trajectory.

Moderna (MRNA) trades at $225.00, up 14.52% in 24 hours, approaching its 52-week high. The stock shows strong technical momentum with bullish moving averages and support at $194. Fundamentally, while revenue has declined from pandemic peaks to $1.92B in 2025, the company continues to beat EPS expectations and maintains a robust pipeline in oncology and respiratory vaccines. Recent inclusion in the Nasdaq-100 index has generated positive momentum, though valuation metrics remain elevated with a P/S ratio of 35.08.

Outlook remains bifurcated - significant growth potential exists in the cancer vaccine pipeline and respiratory vaccine expansion, but current valuations appear stretched relative to financial performance. Key risks include execution challenges in new therapeutic areas, competitive pressure from Pfizer/BioNTech, and dependence on pipeline success beyond COVID-19 vaccines. Analyst consensus shows cautious optimism with a $115.70 price target despite recent downgrades.